Profile: BioMS medical corp is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of multiple sclerosis (MS). The technology, dirucotide, is a synthetic myelin basic protein peptide comprised of 17 amino acids. It is intravenously injected into MS patients as a therapeutic treatment. Dirucotide s a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein. Dirucotide has been developed for the treatment of autoimmune disease, caused by immune attack against normal components of the central nervous system.